Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Stocks and securities in focus

Security Change (%) 1w ▼ 1m 1y YTD 3y 5y
Novavax Inc. 97.310% 80.837% 108.011% 0.917% 84.927% -93.750% 26.254%
Inogen Inc. 2.610% 22.901% 12.587% -21.078% 51.887% -85.364% -
Bastide Le Confort -1.020% 6.339% 28.874% -29.874% -29.620% -56.707% -
Catalyst Pharmaceutical Partners Inc 0.380% 5.679% 1.684% -7.183% -4.794% 272.201% 409.470%
Adocia -0.700% 2.372% -5.683% 127.404% -26.616% -5.061% -50.742%
Fate Therapeutics Inc. 9.850% 0.317% -38.485% -21.923% 6.665% -93.920% -
BeiGene Ltd ADR -5.100% -0.662% 7.914% -33.036% -9.091% -40.000% -
Chromadex Corp -1.120% -2.286% -6.044% 155.224% 155.224% -44.839% -
Evolus Inc -1.650% -3.252% 1.709% 39.181% 31.492% 59.732% -
Enlivex Therapeutics Ltd. -1.380% -4.027% -61.141% -43.254% -36.161% -82.346% -
Viking Therapeutics Inc -7.140% -4.337% 2.549% 230.818% 291.078% 1342.616% -
Cytokinetics Inc. -0.840% -4.918% -16.547% 66.667% -24.183% 198.969% -
Medigene AG 1.010% -5.145% -31.395% -11.940% -7.233% -62.516% -83.095%
Adaptimmune Therapeutics PLC ADR -7.010% -7.143% -12.605% -18.110% 66.400% -73.196% -
Ocular Therapeutix Inc. -5.620% -8.170% -28.513% -10.923% 25.357% -57.920% 62.396%
X4 Pharmaceuticals, Inc. -2.410% -8.714% -14.826% -32.911% 25.577% - -
Salarius Pharmaceuticals Inc. 2.480% -8.811% 2.985% -70.216% -25.405% -98.392% -99.993%
Ardelyx Inc. -3.860% -10.646% 8.770% 81.814% 24.879% 33.667% -
Akebia Therapeutics Inc. -5.620% -12.373% -22.668% 19.807% -4.522% -53.375% -
Gritstone Oncology Inc -17.770% -18.396% -16.952% -69.813% -60.845% -90.515% -
Cytomx Therapeutics Inc -15.850% -55.310% -5.969% 10.890% 32.020% -72.574% -
MacroGenics Inc. -77.710% -78.352% -81.918% -53.424% -65.844% -88.752% -
Amneal Pharmaceuticals Inc 0.830% - - - - - -
Apellis Pharmaceuticals -1.890% - - - - - -